559 related articles for article (PubMed ID: 31587511)
1. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
Mason R; Dearden HC; Nguyen B; Soon JA; Smith JL; Randhawa M; Mant A; Warburton L; Lo S; Meniawy T; Guminski A; Parente P; Ali S; Haydon A; Long GV; Carlino MS; Millward M; Atkinson VG; Menzies AM
Pigment Cell Melanoma Res; 2020 Mar; 33(2):358-365. PubMed ID: 31587511
[TBL] [Abstract][Full Text] [Related]
2. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
[TBL] [Abstract][Full Text] [Related]
3. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.
Okuma T; Furudate S; Kambayashi Y; Hashimoto A; Aiba S; Fujimura T
J Dermatol; 2021 Sep; 48(9):1419-1422. PubMed ID: 34002878
[TBL] [Abstract][Full Text] [Related]
9. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
10. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
[TBL] [Abstract][Full Text] [Related]
11. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
14. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F
Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485
[TBL] [Abstract][Full Text] [Related]
15. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
McDermott DF; Shah R; Gupte-Singh K; Sabater J; Luo L; Botteman M; Rao S; Regan MM; Atkins M
Qual Life Res; 2019 Jan; 28(1):109-119. PubMed ID: 30191365
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Wolchok JD; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Butler MO; Hill A; Márquez-Rodas I; Haanen JBAG; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bas T; Ritchings C; Larkin J; Hodi FS
J Clin Oncol; 2022 Jan; 40(2):127-137. PubMed ID: 34818112
[TBL] [Abstract][Full Text] [Related]
17. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
18. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
19. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
20. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
